Multiple Sclerosis (MS) Normal-appearing white matter (NAWM) Microglia Axon Inflammation VCAM-1 Sphingosine S1P1 Wallerian degeneration A B S T R A C T Inflammatory-like changes in the white matter (WM) are commonly observed in conditions of axonal degeneration by different etiologies. This study is a systematic comparison of the principal features of the inflammatory-like changes in the WM in different pathological conditions characterized by axonal damage/degeneration, focusing in particular on Multiple Sclerosis (MS) normal-appearing white matter (NAWM) compared to non immune-mediated disorders. The study was performed on sections of NAWM from 15 MS cases, 11 cases of non immune-mediated disorders with wallerian axonal degeneration (stroke, trauma, amyotrophic lateral sclerosis), 3 cases of viral encephalitis, 6 control cases.
Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study M Common features of the inflammatory-like changes observed in all of the conditions of WM pathology were diffuse endothelial expression of VCAM-1, microglial activation with expression of M2 markers, increased expression of sphingosine receptors. Inflammation in MS NAWM was characterized, compared to non immunemediated conditions, by higher VCAM-1 expression, higher density of perivascular lymphocytes, focal perivascular inflammation with microglial expression of M1 markers, ongoing acute axonal damage correlating with VCAM-1 expression but not with microglia activation.
Inflammatory changes in MS NAWM share all the main features observed in the WM in non immune-mediated conditions with wallerian axonal degeneration (with differences to a large extent more quantitative than qualitative), but with superimposition of disease-specific perivascular inflammation and ongoing acute axonal damage.
Background
A complex relationship exists between axonal damage and inflammation in the CNS white matter (WM). Inflammation can induce axonal dysfunction and damage, through mechanisms well characterized in immunemediated disorders, for example as observed in acute Multiple Sclerosis (MS) demyelinating lesions (Smith and McDonald, 2003) . However, also axonal damage/degeneration due to any other pathological condition determines secondary inflammatory-like changes in the WM, through yet not fully known damage signals (Hussain et al., 2014; Russo and McGavern, 2015; Burda and Sofroniew, 2014; Amor et al., 2014) . These inflammatory changes can be observed in experimental models of CNS lesions and can be found in the WM in any non-immune mediated neurological disorder with wallerian axonal degeneration (Griffin et al., 1992; Raivich et al., 1998; Graves et al., 2004; Griffiths et al., 2010; Palin et al., 2008) . They are known to differ both quantitatively and qualitatively from "real" brain inflammation that is observed in immune-mediated or infectious neurological disorders (Estes and Mc Allister, 2014; Graeber, 2014) . However, systematic studies evaluating differences and similarities between different conditions of WM pathology are lacking.
Widespread inflammatory changes in the normal-appearing white matter (NAWM), distant from focal demyelinating lesions, are a distinctive feature of MS (Kutzelnigg et al., 2005; Filippi and Rocca, 2005; Zeis et al., 2008; Frischer et al., 2009 ). Several studies have described the pathological changes in MS NAWM, but little data is available on the specificity of such findings and on comparisons with other conditions of WM pathology from other causes. Widespread wallerian axonal degeneration is known to occur in MS NAWM (Evangelou et al., 2000; Casanova et al., 2003; Dziedzic et al., 2010) .
The aim of this study was to perform a systematic comparison of the principal features of the inflammatory-like changes observed in the WM, in several pathological conditions characterized by axonal damage/ http://dx.doi.org/10.1016/j.jneuroim.2017.09.004 Received 13 July 2017; Received in revised form 28 August 2017; Accepted 6 September 2017
